Loading…
Loading…
EQUITY / NASDAQ · XNMS
Neuphoria Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →07/01/2025 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗3.47 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 3.47 USD · Volume 12,586
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
07/01/2025 – 06/30/2026 · Units
| Metric | 2026 / Year end | 2025 / Year end | Change |
|---|---|---|---|
| Revenue | 1,174,165 USD | 15,649,448 USD | -92.50% |
| Operating profit | -16,451,066 USD | -1,129,091 USD | — |
| Net income | -13,451,931 USD | -369,632 USD | — |
| Operating cash flow | -12,353,074 USD | 77,229 USD | -16,095.38% |
| Cash and cash equivalents | 19,865,531 USD | 14,210,745 USD | +39.79% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Year end07/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 207/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2024 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 306/30/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 19,865,531 USD | 19,440,655 USD | — | — | — | — | 14,210,745 USD | 14,210,745 USD |
| Financing cash flowCash flow statement | 17,915,883 USD | — | 17,915,883 USD | — | 17,915,883 USD | — | 1,528,276 USD | — |
| Net incomeIncome statement | -13,451,931 USD | -505,063 USD | -8,547,475 USD | 1,864,092 USD | -8,042,412 USD | -9,906,504 USD | -369,632 USD | — |
| Operating cash flowCash flow statement | -12,353,074 USD | — | -13,566,928 USD | — | -10,230,463 USD | — | 77,229 USD | — |
| Operating profitIncome statement | -16,451,066 USD | -1,211,649 USD | -10,925,151 USD | — | -9,713,502 USD | — | -1,129,091 USD | — |
| RevenueIncome statement | 1,174,165 USD | — | — | — | — | — | 15,649,448 USD | — |
| Total assetsBalance sheet | 28,709,016 USD | 34,809,200 USD | — | — | — | — | 28,589,614 USD | 28,589,614 USD |
| Total equityBalance sheet | 24,600,022 USD | 29,423,944 USD | — | 29,700,824 USD | — | 12,510,187 USD | 19,002,574 USD | 19,002,574 USD |
| Total liabilitiesBalance sheet | 4,108,994 USD | 5,385,256 USD | — | — | — | — | 9,587,040 USD | 9,587,040 USD |
| Report source | Open report ↗ Published: 09/18/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 02/17/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 09/18/2026 | Open report ↗ Published: 05/15/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.